Cargando…

Combination antiretroviral drugs in PLGA nanoparticle for HIV-1

BACKGROUND: Combination antiretroviral (AR) therapy continues to be the mainstay for HIV treatment. However, antiretroviral drug nonadherence can lead to the development of resistance and treatment failure. We have designed nanoparticles (NP) that contain three AR drugs and characterized the size, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Destache, Christopher J, Belgum, Todd, Christensen, Keith, Shibata, Annemarie, Sharma, Akhilesh, Dash, Alekha
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807870/
https://www.ncbi.nlm.nih.gov/pubmed/20003214
http://dx.doi.org/10.1186/1471-2334-9-198
_version_ 1782176436263583744
author Destache, Christopher J
Belgum, Todd
Christensen, Keith
Shibata, Annemarie
Sharma, Akhilesh
Dash, Alekha
author_facet Destache, Christopher J
Belgum, Todd
Christensen, Keith
Shibata, Annemarie
Sharma, Akhilesh
Dash, Alekha
author_sort Destache, Christopher J
collection PubMed
description BACKGROUND: Combination antiretroviral (AR) therapy continues to be the mainstay for HIV treatment. However, antiretroviral drug nonadherence can lead to the development of resistance and treatment failure. We have designed nanoparticles (NP) that contain three AR drugs and characterized the size, shape, and surface charge. Additionally, we investigated the in vitro release of the AR drugs from the NP using peripheral blood mononuclear cells (PBMCs). METHODS: Poly-(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) containing ritonavir (RTV), lopinavir (LPV), and efavirenz (EFV) were fabricated using multiple emulsion-solvent evaporation procedure. The nanoparticles were characterized by electron microscopy and zeta potential for size, shape, and charge. The intracellular concentration of AR drugs was determined over 28 days from NPs incubated with PBMCs. Macrophages were imaged by fluorescent microscopy and flow cytometry after incubation with fluorescent NPs. Finally, macrophage cytotoxicity was determined by MTT assay. RESULTS: Nanoparticle size averaged 262 ± 83.9 nm and zeta potential -11.4 ± 2.4. AR loading averaged 4% (w/v). Antiretroviral drug levels were determined in PBMCs after 100 μg of NP in 75 μL PBS was added to media. Intracellular peak AR levels from NPs (day 4) were RTV 2.5 ± 1.1; LPV 4.1 ± 2.0; and EFV 10.6 ± 2.7 μg and continued until day 28 (all AR ≥ 0.9 μg). Free drugs (25 μg of each drug in 25 μL ethanol) added to PBMCs served as control were eliminated by 2 days. Fluorescence microscopy and flow cytometry demonstrated phagocytosis of NP into monocytes-derived macrophages (MDMs). Cellular MTT assay performed on MDMs demonstrated that NPs are not significantly cytotoxic. CONCLUSION: These results demonstrated AR NPs could be fabricated containing three antiretroviral drugs (RTV, LPV, EFV). Sustained release of AR from PLGA NP show high drug levels in PBMCs until day 28 without cytotoxicity.
format Text
id pubmed-2807870
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28078702010-01-19 Combination antiretroviral drugs in PLGA nanoparticle for HIV-1 Destache, Christopher J Belgum, Todd Christensen, Keith Shibata, Annemarie Sharma, Akhilesh Dash, Alekha BMC Infect Dis Research Article BACKGROUND: Combination antiretroviral (AR) therapy continues to be the mainstay for HIV treatment. However, antiretroviral drug nonadherence can lead to the development of resistance and treatment failure. We have designed nanoparticles (NP) that contain three AR drugs and characterized the size, shape, and surface charge. Additionally, we investigated the in vitro release of the AR drugs from the NP using peripheral blood mononuclear cells (PBMCs). METHODS: Poly-(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) containing ritonavir (RTV), lopinavir (LPV), and efavirenz (EFV) were fabricated using multiple emulsion-solvent evaporation procedure. The nanoparticles were characterized by electron microscopy and zeta potential for size, shape, and charge. The intracellular concentration of AR drugs was determined over 28 days from NPs incubated with PBMCs. Macrophages were imaged by fluorescent microscopy and flow cytometry after incubation with fluorescent NPs. Finally, macrophage cytotoxicity was determined by MTT assay. RESULTS: Nanoparticle size averaged 262 ± 83.9 nm and zeta potential -11.4 ± 2.4. AR loading averaged 4% (w/v). Antiretroviral drug levels were determined in PBMCs after 100 μg of NP in 75 μL PBS was added to media. Intracellular peak AR levels from NPs (day 4) were RTV 2.5 ± 1.1; LPV 4.1 ± 2.0; and EFV 10.6 ± 2.7 μg and continued until day 28 (all AR ≥ 0.9 μg). Free drugs (25 μg of each drug in 25 μL ethanol) added to PBMCs served as control were eliminated by 2 days. Fluorescence microscopy and flow cytometry demonstrated phagocytosis of NP into monocytes-derived macrophages (MDMs). Cellular MTT assay performed on MDMs demonstrated that NPs are not significantly cytotoxic. CONCLUSION: These results demonstrated AR NPs could be fabricated containing three antiretroviral drugs (RTV, LPV, EFV). Sustained release of AR from PLGA NP show high drug levels in PBMCs until day 28 without cytotoxicity. BioMed Central 2009-12-09 /pmc/articles/PMC2807870/ /pubmed/20003214 http://dx.doi.org/10.1186/1471-2334-9-198 Text en Copyright ©2009 Destache et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Destache, Christopher J
Belgum, Todd
Christensen, Keith
Shibata, Annemarie
Sharma, Akhilesh
Dash, Alekha
Combination antiretroviral drugs in PLGA nanoparticle for HIV-1
title Combination antiretroviral drugs in PLGA nanoparticle for HIV-1
title_full Combination antiretroviral drugs in PLGA nanoparticle for HIV-1
title_fullStr Combination antiretroviral drugs in PLGA nanoparticle for HIV-1
title_full_unstemmed Combination antiretroviral drugs in PLGA nanoparticle for HIV-1
title_short Combination antiretroviral drugs in PLGA nanoparticle for HIV-1
title_sort combination antiretroviral drugs in plga nanoparticle for hiv-1
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2807870/
https://www.ncbi.nlm.nih.gov/pubmed/20003214
http://dx.doi.org/10.1186/1471-2334-9-198
work_keys_str_mv AT destachechristopherj combinationantiretroviraldrugsinplgananoparticleforhiv1
AT belgumtodd combinationantiretroviraldrugsinplgananoparticleforhiv1
AT christensenkeith combinationantiretroviraldrugsinplgananoparticleforhiv1
AT shibataannemarie combinationantiretroviraldrugsinplgananoparticleforhiv1
AT sharmaakhilesh combinationantiretroviraldrugsinplgananoparticleforhiv1
AT dashalekha combinationantiretroviraldrugsinplgananoparticleforhiv1